Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on Merck & Co.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

After a challenging 2013, Merck (MRK 1.80%) is pushing ahead with a new strategy to try to reinvigorate its top- and bottom-line growth prospects over the next few years.

2011 - A Year of Accelerated Growth and Execution As Merck entered 2011, the company focused on accelerating top-line growth, reducing costs, allocating resources to drive growth and advancing and ...

Still, the fact remains that Merck has more work to do to maintain a reasonable growth trajectory in the next decade and beyond. Hence, this blue-chip pharma stock doesn't stand out as a top buy ...

Pharmaceutical giant Merck & Co. is pushing forward its pipeline of drugs, including a melanoma drug candidate given US priority review, but it’s also open to acquisitions to accelerate its ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Merck's 2019 investor day was held on the Upper East Side of Manhattan. Emma Court / Business Insider Merck executives told that story of growth and change on Thursday, the drugmaker's first ...

The pharmaceutical industry is currently grappling with a major investment problem. Since 2004, the shares of most major pharmaceutical companies have been lagging behind the S&P 500. A few ...

In a report released today, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $148.00. Evan Seigerman has given his Buy ...